Scottish Cohort Links Home BP Telemonitoring to 20% Lower Cardiovascular Events

The study followed patients from 2019-2022, comparing those who transmitted home readings with automated reminders against standard office-based monitoring. Telemonitoring participants showed blood-pressure drops within three months that persisted beyond one year, accompanied by lower rates of stroke, myocardial infarction, heart failure admissions, and all-cause mortality after adjustment for age, medication count, and deprivation. Residual confounding remains possible because telemonitoring users were younger and less deprived. Prior randomized trials, including the TASMINH4 study in the BMJ and a 2023 Lancet meta-analysis of 14,000 participants, demonstrated 5–10 mmHg systolic reductions with telemonitoring but lacked power for hard endpoints; this Scottish data extends those findings to population-level outcomes. Scotland’s early scaling to 130,000 users offers a natural experiment on implementation equity. Extending access to higher-risk groups in deprived postcodes will require targeted outreach and device subsidies. A forthcoming cluster-randomized trial comparing expanded telemonitoring against enhanced usual care in 50,000 patients is needed to confirm causality and cost-effectiveness before nationwide NHS adoption.